Page last updated: 2024-12-09

(4-methoxyphenyl)-(4-methyl-1-piperazinyl)methanethione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(4-Methoxyphenyl)-(4-methyl-1-piperazinyl)methanethione, also known as **thiocolchicoside**, is a **nonsteroidal anti-inflammatory drug (NSAID)**.

Here's why it's important for research:

* **Mechanism of Action:** Thiocolchicoside is a potent **inhibitor of microtubule assembly**. Microtubules are crucial for various cellular processes, including cell division, cell migration, and intracellular transport. By inhibiting microtubule assembly, thiocolchicoside can have **anti-inflammatory and analgesic effects**.
* **Potential Therapeutic Applications:** Thiocolchicoside has shown promise in preclinical studies for treating various conditions, including:
* **Muscle Spasm and Pain:** It acts as a muscle relaxant, potentially making it useful for treating conditions like low back pain and muscle strains.
* **Inflammation:** Its anti-inflammatory properties could be valuable in managing inflammatory conditions like arthritis.
* **Cancer:** Some research suggests it may have potential in treating certain types of cancer due to its ability to interfere with cell division.
* **Safety and Toxicity:** Thiocolchicoside is generally considered safe and well-tolerated, but some side effects can occur, such as gastrointestinal upset, dizziness, and drowsiness. Further research is needed to fully understand its long-term safety profile.

**Current Research:**

* **Novel Drug Delivery Systems:** Researchers are exploring new ways to deliver thiocolchicoside, such as transdermal patches and nanoparticles, to improve its effectiveness and reduce side effects.
* **Combination Therapies:** Combining thiocolchicoside with other medications, like opioids or anti-inflammatory agents, is being investigated to enhance pain relief and treatment efficacy.
* **Mechanism of Action Studies:** Ongoing research aims to further elucidate the precise molecular mechanisms by which thiocolchicoside exerts its anti-inflammatory and analgesic effects.

**Conclusion:**

(4-Methoxyphenyl)-(4-methyl-1-piperazinyl)methanethione (thiocolchicoside) is a promising NSAID with potential therapeutic applications. Further research is necessary to fully understand its clinical efficacy, safety, and potential for improving patient care.

Cross-References

ID SourceID
PubMed CID804311
CHEMBL ID1602583
CHEBI ID105991

Synonyms (14)

Synonym
smr000142145
MLS000534728 ,
1-[(4-methoxyphenyl)carbonothioyl]-4-methylpiperazine
(4-methoxyphenyl)(4-methylpiperazin-1-yl)methanethione
STK221425
CHEBI:105991
AKOS000347976
(4-methoxyphenyl)-(4-methylpiperazin-1-yl)methanethione
HMS2326E16
CHEMBL1602583
(4-methoxyphenyl)-(4-methyl-1-piperazinyl)methanethione
Q27183786
sr-01000250297
SR-01000250297-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.10000.003245.467312,589.2998AID2517
phosphopantetheinyl transferaseBacillus subtilisPotency25.11890.141337.9142100.0000AID1490
regulator of G-protein signaling 4Homo sapiens (human)Potency50.11870.531815.435837.6858AID504845
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID624296
neuropeptide S receptor isoform AHomo sapiens (human)Potency3.98110.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]